期刊
MOLECULAR ONCOLOGY
卷 15, 期 2, 页码 347-349出版社
WILEY
DOI: 10.1002/1878-0261.12880
关键词
11q deletion; anti-GD2 therapy; immune checkpoint inhibition; microRNAs
类别
资金
- NIH [R35 CA220500]
- Giulio D'Angio Endowed Chair
This study focused on the impact of hemizygous deletion of chromosome 11q on the response to immunotherapy in high-risk neuroblastoma, and explored potential transcriptional and post-transcriptional pathways that could be therapeutically targeted with biomarkers.
In this issue, Coronado et al. attempt to improve our understanding of the factors affecting the response to immunotherapy in a large subset of high-risk neuroblastoma with hemizygous deletion of chromosome 11q. By using several computational approaches, the authors study potential transcriptional and post-transcriptional pathways that may affect the response to immunotherapy and further be leveraged therapeutically in a biomarker-directed fashion.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据